Target intelligence / Profile preview

Ricinus communis agglutinin (RCA120)

Target
RCA120
Molecular classification
Lectin, Type II Ribosome-inactivating protein, Glycoprotein
01

Overview

Ricinus communis agglutinin (RCA), specifically the RCA120 form, is a galactose-binding lectin isolated from the seeds of the castor bean plant (Ricinus communis) [UniProt, PubChem]. It is a member of the type II ribosome-inactivating protein (RIP) family and is structurally related to the highly toxic protein ricin, though RCA120 exists as a 120 kDa tetramer composed of two A-chains and two B-chains [NCBI, Wikipedia]. The B-chains are responsible for high-affinity binding to terminal galactose or N-acetylgalactosamine residues on the surface of eukaryotic cells, facilitating internalization via endocytosis [PubMed]. Once inside the cell, the A-chain functions as an N-glycosidase that depurinates the 28S ribosomal RNA, which irreversibly halts protein synthesis and induces cell death [UniProt]. While RCA is significantly less toxic than ricin due to its larger size and less efficient cytosolic translocation, it remains highly lethal and is used in laboratories to study cell-surface carbohydrates and neuronal pathways [NCBI]. In clinical research, it has been explored as a potential component of immunotoxins for targeted cancer therapy, where it is conjugated to antibodies to specifically eliminate tumor cells [PubMed].

Other names
RCA120Ricinus communis agglutinin IRCA-ICastor bean agglutininRicinus communis lectin
02

Mechanism of action

Binds to terminal galactose residues on cell surfaces via B-chains and inhibits protein synthesis by depurinating 28S ribosomal RNA via A-chains.

03

Biological functions

Carbohydrate bindingCell agglutinationInhibition of protein synthesisInduction of apoptosis
04

Disease associations

Toxin poisoningCancer
05

Safety considerations

Potent cytotoxicityPotential for use as a biological weaponSevere systemic toxicityImmunogenicity
06

Interacting drugs

Lactose

2 more in the full profile.

07

Biomarkers

RicinineRCA-specific antibodies

Beyond the preview

Go deeper on Ricinus communis agglutinin (RCA120).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ricinus communis agglutinin (RCA120).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call